Theravance Biopharma (NASDAQ:TBPH) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.
Valuation and Earnings
This table compares Theravance Biopharma and NuCana’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Theravance Biopharma||$60.37 million||22.21||-$215.52 million||($3.99)||-5.93|
NuCana has lower revenue, but higher earnings than Theravance Biopharma. NuCana is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Theravance Biopharma has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500. Comparatively, NuCana has a beta of 3.19, suggesting that its stock price is 219% more volatile than the S&P 500.
Insider & Institutional Ownership
84.2% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 36.1% of NuCana shares are owned by institutional investors. 6.6% of Theravance Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Theravance Biopharma and NuCana’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings for Theravance Biopharma and NuCana, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Theravance Biopharma currently has a consensus target price of $49.33, indicating a potential upside of 108.42%. NuCana has a consensus target price of $23.33, indicating a potential upside of 159.55%. Given NuCana’s higher possible upside, analysts clearly believe NuCana is more favorable than Theravance Biopharma.
NuCana beats Theravance Biopharma on 8 of the 12 factors compared between the two stocks.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant. YUPELRI, a long-acting muscarinic antagonist, for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD); and Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders. The company's product candidates also comprise Selective 5-HT4 Agonist for treating gastrointestinal motility disorders; Gut-selective Pan-Janus Kinase Inhibitor Program for treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis; TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TD-0714 and Neprilysin Inhibitor Program, which have completed Phase I clinical studies for heart failure and chronic kidney disease, including diabetic nephropathy. In addition, it focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium bromide, and vilanterol for the treatment of COPD and asthma; the inhaled bifunctional muscarinic antagonist-beta2 agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
NuCana Company Profile
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.